Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (NCT07096778)
A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (11 items).
Location: Mayo Clinic Arizona — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Use of any investigational agent, chemotherapy, immunotherapy or anticancer agent from a previous clinical study within 14 days or 5 half-lives of first dose of study treatment, whichever is shortest; any antibody based therapy within 30 days
- Prior treatment with p300/CBP bromodomain inhibitors
- Known or suspected severe allergies to any active or inactive ingredients in the study medications (inobrodib, pomalidomide, dexamethasone) or any prior immunomodulatory drug (lenalidomide, thalidomide)
- Treatment with medicines or herbal supplements or foods (e.g. strong CYP3A4 inducers or inhibitors) that would interfere with treatment
- Major surgery within 4 weeks of the first dose of study treatment
- Live vaccine within 4 weeks of study treatment
- Active or unresolved adverse events
- Active malignancies (progressing or requiring change in treatment) in the last 24 months other than multiple myeloma
- Female patients who are pregnant or breast-feeding at any time during the study
- Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (30 Sites)
Showing the first 25 of 30 sites.
- Mayo Clinic Arizona — Phoenix, Arizona
- University of California, San Francisco — San Francisco, California
- Mayo Clinic Florida — Jacksonville, Florida
- H Lee Moffitt Cancer Center & Research Institute — Tampa, Florida
- Winship Cancer Institute — Atlanta, Georgia
- University of Chicago Medical Center — Chicago, Illinois
- American Oncology Partners, PA — Bethesda, Maryland
- Dana-Farber Cancer Institute — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Mayo Clinic — Rochester, Minnesota
- Washington University School of Medicine — St Louis, Missouri
- University of Nebraska Medical Center — Omaha, Nebraska
- John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- Levine Cancer Institute — Charlotte, North Carolina
- Wake Forest University Health Sciences — Winston-Salem, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- University of Pennsylvania, Abramson Cancer Center — Philadelphia, Pennsylvania
- Fred Hutchinson Cancer Center — Seattle, Washington
- Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
- The Christie NHS Foundation Trust — Withington, Greater Manchester
- Royal Marsden NHS Foundation Trust — Sutton, London
- University Hospital of Wales — Cardiff, Wales
- The Clatterbridge Cancer Centre NHS Foundation Trust — Bebington, Wirral
- Western General Hospital — Edinburgh,
📞 Contact the Study Coordinator
Phone: +44 1799 531130
Email: DOMMINO-1@cellcentric.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma Refractory
- Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager — Lévis, Quebec
- Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma — Toronto, Ontario
- Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma — Miami, Florida
Explore by condition: All Multiple Myeloma Refractory clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.